Cornerstone sharpens US hospital focus, acquiring EKR Therapeutics along with Cardene IV, Retavase
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics is once again sharpening its strategic focus on US hospital and specialty markets, as the Cary, North Carolina drug maker revealed that it has entered into a definitive agreement to acquire EKR Therapeutics, a privately held specialty pharma company specialising in the acute-care hospital setting.